Axsome Therapeutics, Inc. (NASDAQ:AXSM) Announces Earnings Results
Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its earnings results on Wednesday. The company reported ($0.30) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.01, MarketWatch Earnings reports.
Axsome Therapeutics (NASDAQ:AXSM) traded down 5.13% during trading on Thursday, hitting $5.55. The stock had a trading volume of 129,900 shares. Axsome Therapeutics has a 1-year low of $3.53 and a 1-year high of $9.11. The firm’s 50-day moving average price is $5.66 and its 200-day moving average price is $4.60. The stock’s market cap is $131.01 million.
ILLEGAL ACTIVITY NOTICE: “Axsome Therapeutics, Inc. (NASDAQ:AXSM) Announces Earnings Results” was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/axsome-therapeutics-inc-nasdaqaxsm-announces-earnings-results/1468916.html.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research raised Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a report on Wednesday, May 24th. BTIG Research assumed coverage on Axsome Therapeutics in a report on Friday, May 19th. They issued a “buy” rating and a $14.00 price target for the company. Aegis reissued a “buy” rating and issued a $20.00 price target on shares of Axsome Therapeutics in a report on Thursday, May 25th. ValuEngine raised Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 21st. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $31.00 price target (up from $28.00) on shares of Axsome Therapeutics in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $17.08.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.